Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells (Q40077017)

17 September 2017

title

Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells (English)

1 reference

17 September 2017

1 reference

A Morandi

4

0 references

Elisabetta Rovida

object named as

E Rovida

3

0 references

author name string

V Barbetti

1

1 reference

17 September 2017

A Gozzini

2

1 reference

17 September 2017

E Spinelli

5

1 reference

17 September 2017

G Fossati

6

1 reference

17 September 2017

P Mascagni

7

1 reference

17 September 2017

M Lübbert

8

1 reference

17 September 2017

P Dello Sbarba

9

1 reference

17 September 2017

V Santini

10

1 reference

17 September 2017

language of work or name

English

0 references

publication date

24 September 2007

1 reference

17 September 2017

1 reference

17 September 2017

volume

27

1 reference

17 September 2017

issue

12

1 reference

17 September 2017

page(s)

1767-1778

1 reference

Common themes in the pathogenesis of acute myeloid leukemia

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Nuclear matrix, dynamic histone acetylation and transcriptionally active chromatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Oncogenic transcription factors in the human acute leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Inducible expression of AML1-ETO fusion protein endows leukemic cells with susceptibility to extrinsic and intrinsic apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

The transcriptional coactivators p300 and CBP are histone acetyltransferases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210820

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1210820

1 reference

Dimensions Publication ID

17 September 2017

1021125611

0 references

1 reference